Genome Editing Market Share and Trends 2025 to 2034

Revenue, 2024

USD 9.33 Bn

Forecast Year, 2034

USD 43.19 Bn

CAGR, 2025 - 2034

16.56%

Report Coverage

Global

What is Genome Editing Market Size?

The global genome editing market size is estimated at USD 10.91 billion in 2025 and is predicted to increase from USD 12.76 billion in 2026 to approximately USD 43.19 billion by 2034, expanding at a CAGR of 16.56% from 2025 to 2034. The rising prevalence of down syndrome and cystic fibrosis across the world is driving the growth of the genome editing market.

Market Highlights

• North America led the market with the largest revenue share of 48% in 2024.
• Asia Pacific is expected to expand at a solid CAGR of 18.75% during the forecast period.
• By technology, the CRISPR/Cas9 segment has contributed more than 45% of revenue share in 2024.
• By technology, the ZFN segment is projected to grow at a notable CAGR of 16.57% during the forecast period.
• By delivery methods, the ex-vivo segment has held a major revenue share of 52% in 2024.
• By delivery methods, the in-vivo segment is expected to grow with the highest CAGR of 19.24% during the forecast period.
• By application, the genetic engineering segment dominated the market in 2024.
• By application, the clinical applications segment is estimated to expand at the solid CAGR of 13.20% during the forecast period.
• By mode, the contract segment led the market in 2024.
• By mode, the in-house segment is expected to be the fastest-growing segment in the market.
• By end-use, the biotechnology and pharmaceutical companies segment has held a biggest revenue share of 51% in 2024.
• By end-use, the academic and research institutions segment is estimated to at a remarkable CAGR of 19.23% during the forecast period.

Market Overview

The genome editing market is one of the most important industries in the biotechnology sector. This industry mainly deals with altering genetic materials in a living organism to treat any genetic disorder. Genome editing works in the principle of inserting, deleting, or replacing DNA sequences in a cell of a living organism. It involves various technologies that mainly include (CRISPR)/Cas9, ZFN, Meganuclease, TALENs/MegaTALs, and some others. There are two delivery methods of gene transfer in different cells: ex-vivo and in-vivo.

The main applications of genome engineering include cell line engineering, plant genetic engineering, animal genetic engineering, and other clinical applications. There are several end users of this industry, mainly including biotechnology and pharmaceutical companies, contract research organizations, and academic and government research institutes. This industry is expected to grow exponentially with the growth in the biotech and healthcare industries.

Genome Editing Market Growth Factors

• Technological advancements in the biotechnology industry are expected to drive the growth of the genome editing market.
• The rising government initiatives to strengthen the genetic engineering sector have driven the market growth.
• The growing developments in the research and innovation centres across the world fosters the market growth.
• The rising prevalence of rare diseases among the people across the world has boosted the market growth.
• The growing investments from public and private sector entities for developing the genome editing industries also boost the market growth.
• The rise in the number of genetic diseases is likely to impact the market growth positively.
• The growing development in DNA editing technologies also propels the market growth to some extent.
• Rapid advancements in ZFN tools around the world are expected to boost the growth of the genome editing market.
• The ongoing developments in animal and plant genetic engineering boost the market growth.
• The advancements in ex-vivo gene delivery methods have impacted the market growth positively.

Genome Editing Market Outlook

• Industry Growth Overview: Between 2025 and 2030, this market is expected to rise significantly due to the numerous government initiatives aimed at developing the biotechnology sector coupled with rapid investment by market players for opening up new research and development centres across the world.
• Major Investors:Numerous market players are actively entering this market, drawn by product launches, partnerships, R&D and some others. Various genome editing companies such as Transposagen Biopharmaceuticals, Inc. Genscript Biotech Corp, New England Biolabs and some others have started investing rapidly for developing advanced gene editing technologies around the globe.
• Startup Ecosystem: Various startup companies are engaged in developing advanced gene editing solutions. The prominent startup brands dealing in genome editing consists of Beam Therapeutics, Verve Therapeutics, Caribou Biosciences and some others.

Market Scope

Market Dynamics

Drivers

Rising applications of CRISPR technology

The drastic evolution of CRISPR/CAS9 tools has played an important role in the development of the genome editing industry. The rising application of CRISPR technology for manipulating genomic DNA from host organisms to develop effective therapeutics has gained prominent attention from different industry verticals. The growing demand for CRISPR-based genetic editing technology in research of cardiovascular disease along with growing use of CRISPR-Cas systems in precise genome editing including base editing and prime editing has impacted the market growth positively. Moreover, biotech companies are constantly developing advanced CRISPR therapies for the treatment of rare diseases, which is likely to drive the growth of the genome editing market during the forecast period.

• In November 2023, Vertex Pharmaceuticals made an announcement stating that the United Kingdom (U.K.) Medicines and Healthcare Products Regulatory Agency (MHRA) approved CASGEVY for commercial use. CASGEVY is a CRISPR/Cas9 gene-edited therapy that will be used for treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).

Restraint

Ethical concerns of genomic engineering

The application of genome editing has gained utmost importance in recent times. Although there are several advantages of gene editing, it comes with several problems that mainly include ethical issues. The ethical issue arises due to the adoption of germline gene therapies for altering genes in the present generation to prevent future generations from any genetic disorders that may not be liked by some families. Thus, growing ethical concerns in genetic editing are likely to restrain the growth of the genome editing market.

Opportunity

Development of AI-based CRISPR technology

Advancements in AI have played an important role in the development of the genome editing industry. The rising integration of AI in genome engineering has gained popularity. The development of AI-based CRISPR therapies has been found to be effective in treating several rare diseases. Thus, the rising development of AI-based CRISPR technology is expected to create ample growth opportunities for the market players in the future.

• In May 2024, Profluent launched AI-enabled OpenCRISPR-1. OpenCRISPR-1 is an AI-based gene editor that consists of a Cas9 protein and guide RNA that can be used to develop therapies for the treatment of rare diseases.

Segment Insights

Technology Insights

The CRISPR/Cas9 segment held the largest market share in 2024. The growth of this segment is generally driven by the rise in advancement in genetic engineering. Also, rising development in genome editing technologies, along with the increasing investments in research and development activities of CRISPR technology, is expected to drive the market growth. Moreover, the growing demand for innovative gene editing tools, along with rising R&D activities of CRISPR technology by biotech companies for manufacturing advanced genetic tools, is also likely to boost the growth of the genome editing market.

• In February 2024, Tome Biosciences launched a CRISPR tool. This tool is capable of inserting large DNA sequences into the genome in any position for gene correction in vivo delivery method.

The ZFN segment is expected to be the fastest-growing segment during the forecast period. This segment is generally driven by the rising demand for artificial restriction enzymes. Also, rising application of Zinc-finger nuclease technology for manufacturing therapeutics for genetic diseases. Moreover, the rise in the number of patients suffering from HIV and Hunter's Syndrome has increased the demand for ZFN technology for manufacturing effective drugs to treat these diseases. This, in turn, drives the growth of the genome editing market.

Delivery Method Insights

The ex-vivo segment dominated the market in 2024. The growth of this segment is generally driven by the growing developments in gene therapy. Also, the rising trend of gene harvesting for treating blood disorders, along with growing development in CAR-T cell therapies, is likely to boost the growth of the genome editing market. Moreover, ongoing research by scientists on the use of ex-vivo gene therapies to treat fatty liver and obesity among patients across the world is further driving market growth.

The in-vivo segment is expected to be the fastest-growing segment during the forecast period. This segment is generally driven by rising developments in viral vector-mediated gene transfer and epigenome editing strategies. Also, the rising application of in-vivo gene therapies for manufacturing medicine to treat liver and nerve diseases boosts the market growth. Moreover, the ongoing trend of inserting new genes into host organisms is driving the growth of the genome editing market during the forecast period.

Application Insights

The genetic engineering segment held the largest market share in the genome editing market in 2024. The growth of this segment is generally driven by the rising developments in cell line engineering. Also, rising advancements in modern sciences related to plant and animal genetic engineering are likely to boost market growth. Moreover, rising investments by governments of several countries to strengthen the genetic engineering sector have driven the growth of the genome editing market.

The clinical applications segment is expected to be the fastest-growing segment during the forecast period. The growth of this segment is generally driven by the rise in the number of genetic disorders among people across the world. Also, the rising emphasis on developing genetic therapies for the treatment of AIDS and cancer boosts the market growth. Moreover, rising demand for clinical applications such as diagnostics and therapy development has driven the growth of the genome editing market during the forecast period.

Mode Insights

The contract segment held the largest share of the genome editing market. The growth of this segment is driven by rising outsourcing activities in genome editing along with the rise in the number of biotech companies providing flexible and low-cost outsourcing offers. Also, growing strategic activities by outsourcing providers of genomic engineering have driven the growth of the genome editing market during the forecast period.

The in-house segment is estimated to be the fastest-growing segment during the forecast period. This segment is generally driven by the growing ownership of supply chains, superior troubleshooting capabilities, and higher potential for developing in-house activities related to genomic engineering. Moreover, the ongoing R&D activities related to the development of in-house genetic therapies to derive maximum profits are likely to drive the growth of the genome editing market.

End-use Insights

The biotechnology and pharmaceutical companies segment held the largest share of the market in 2024. This segment is generally driven by the rise in government initiatives to strengthen the biotechnology and pharmaceutical sectors. Moreover, the rise in the number of research activities for developing novel therapeutics, along with advancements in genetic engineering technologies such as CRISPR and ZFN, is likely to drive market growth. Moreover, several collaborations are taking place among the biotech companies to manufacture drugs for treating genetic diseases, further boosting the market growth. For instance, in June 2022, Precision BioSciences collaborated with Novartis. This collaboration aimed to develop potentially curative treatments for several types of disorders, such as sickle cell disease and some others.

The academic and research institutions segment is expected to witness the fastest growth rate during the forecast period. This segment is generally driven by the rise in the number of biotechnology research and academic institutions across the world. Moreover, the rising interest of students in taking up biotechnology for higher studies, along with rising research activities by scientists to derive new therapeutics for treating serious diseases, has increased the demand for biotech research institutions, thereby driving market growth.

Regional Insights

U.S. Genome Editing Market Size and Growth 2025 to 2034

The U.S. genome editing market size is exhibited at USD 3.67 billion in 2025 and is projected to be worth around USD 14.82 billion by 2034, poised to grow at a CAGR of 16.82% from 2025 to 2034.

North America held the largest genome editing market share in 2024. The growth of this region is mainly driven by rising government initiatives in countries such as the U.S., Canada, Mexico, and others to strengthen the biotechnology sector. For instance, in July 2021, the government of Canada invested around US$ 1.2 billion in developing its therapeutics, vaccine, and biomanufacturing capacity across the country. The rising developments in the healthcare industry, along with the presence of a well-established biotechnology sector, drive the market growth. Also, the rising advancements in science and technology, along with the establishment of several biotechnology research institutions and innovation centers, are likely to drive market growth.

Moreover, the presence of several market players such as Mission Bio, Danaher, Merck, and some others are constantly engaged in developing high-quality genome editing tools and adopting several strategies such as launches, collaborations, and acquisitions, which in turn drive the growth of the respiratory antiviral treatment market in this region.

• In September 2023, Mission Bio launched the Tapestri genome editing solution. This solution is designed to cater to the increasing need for high-resolution analysis of genome editing, functional genomics, and disease modeling.

Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of this segment is mainly driven by the rising prevalence of cancer among the people in this region. According to the Ministry of Health (MOH) of Singapore, in 2022, the number of recorded deaths in Singapore was 26,891, and around 23.9 % of these deaths were caused by cancer. Also, rising investments by public and private sector entities in developing the genetic engineering sector are boosting market growth. The rising incidences of genetic disorders, along with the growing demand for gene editing technologies for manufacturing effective therapeutics, drive the market growth in this region. Moreover, the presence of biotechnology companies such as BioRay, Genkore, Cyrus Therapeutics, Takara Bio, and some others are adopting strategies such as product development and collaborations, which in turn drives the growth of the genome editing market.

• In June 2024, GenKOre collaborated with Revvity. This collaboration is done to develop effective genetic therapies for the treatment of ocular disorders such as Usher Syndrome Type 2A (USH2A) and Leber Congenital Amaurosis 10 (LCA10).

What led Europe to hold a significant share of the genome editing market?

Europe held a significant share of the market. The growing investment by government of numerous countries such as Germany, Italy, France, UK and some others for developing the biotechnology sector has boosted the market expansion. Additionally, the presence of several market players such as CRISPR Therapeutics AG, Cellectis S.A., Horizon Discovery and some others is expected to propel the growth of the genome editing market in this region.

Why Latin America held a considerable share of the genome editing market?

Latin America held a considerable share of the industry. The rising emphasis of biopharma companies to invest rapidly in (CRISPR)/Cas9 technology for developing advanced therapeutics has driven the market growth. Also, numerous government initiatives aimed at developing the healthcare sector is expected to boost the growth of the genome editing market in this region.

How is Middle East & Africa contributing to the genome editing market?

The Middle East & Africa held a notable share of the market. The technological advancements in the genetic engineering sector across numerous countries including UAE, Saudi Arabia, South Africa, Qatar and some others has driven the industrial expansion. Additionally, rapid investment by market players for opening up new biotech research and development centers is expected to drive the growth of the genome editing market in this region.

Key Players in Genome Editing Market and their Offerings

• Editas Medicine: Editas Medicine is a clinical-stage biotechnology company focused on developing and commercializing in vivo gene editing medicines to treat serious diseases. The company's platform uses CRISPR/Cas12a and CRISPR/Cas9 gene editing systems to create a pipeline of medicines for various conditions such as ocular and blood diseases, cancer, and high LDL cholesterol.
• Precision BioSciences: Precision BioSciences is a clinical-stage biotechnology company founded in 2006 that uses its proprietary ARCUS genome editing platform to develop therapies for genetic and infectious diseases. The company's pipeline includes both in vivo gene editing treatments for treating numerous health conditions.
• CRISPR Therapeutics: CRISPR Therapeutics is a Swiss-American biotechnology company that develops gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing technology. The company focuses on a diverse pipeline of therapies, including treatments for hemoglobinopathies (like sickle cell disease and beta-thalassemia), oncology, regenerative medicine, and rare diseases.
• Intellia Therapeutics, Inc.: Press Kit - Intellia TherapeuticsIntellia Therapeutics, Inc. is a clinical-stage biotechnology company that develops gene editing therapies using the CRISPR/Cas9 system to create potentially curative treatments for severe diseases. The company focuses on both "in vivo" (direct delivery into the body) and "ex vivo" (modifying cells outside the body) programs, with projects targeting conditions such as hereditary angioedema, transthyretin amyloidosis, and different types of cancers.
• Caribou Biosciences, Inc: Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited, "off-the-shelf" allogeneic cell therapies for cancer and autoimmune diseases. It uses its proprietary CRISPR hybrid RNA-DNA (chRDNA) technology for advanced precision in its therapies, including the lead candidate CB-010 for B-cell non-Hodgkin lymphoma.
• Danaher Corporation: Danaher Corporation is a global science and technology company based in Washington, D.C., that focuses on life sciences, diagnostics, and biotechnology. The company develops products and solutions to help customers, including healthcare providers and research institutions, solve complex challenges in human health.
• Transposagen Biopharmaceuticals, Inc.: Transposagen Biopharmaceuticals, Inc. is a biotechnology company founded in 2003 in Lexington, Kentucky, that specializes in gene editing technologies and creating genetically modified animal models for disease research and drug discovery. This company provides its products and services to academic institutions, government agencies, and pharmaceutical companies worldwide.
• Genscript Biotech Corp: GenScript Biotech Corp is a global biotechnology company founded in 2002 that provides life science research services and products. This company operates through four main segments including life-science services and products, biologics contract development services, industrial synthetic biology products, and cell therapy.

Segments Covered in the Report

By Technology

• (CRISPR)/Cas9
• ZFN
• Meganuclease
• TALENs/MegaTALs
• Others

By Delivery Method

• Ex-vivo
• In-vivo

By Application

• Genetic Engineering
  • Cell Line Engineering
  • Plant Genetic Engineering
  • Animal Genetic Engineering
  • Others
• Clinical Applications
  • Diagnostics
  • Therapy Development

By Mode

• Contract
• In-house

By End-use

• Biotechnology and Pharmaceutical Companies
• Contract Research Organizations
• Academic And Government Research Institutes

By Region

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa